Highlights
The global Pharmaceuticals and Biotechnology R & D market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Pharmaceuticals and Biotechnology R & D is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Pharmaceuticals and Biotechnology R & D is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Pharmaceuticals and Biotechnology R & D in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Pharmaceuticals and Biotechnology R & D include ROCHE, JOHNSON & JOHNSON, MERCK, NOVARTIS, PFIZER, SANOFI, BAYER, BRISTOL-MYERS SQUIBB and ASTRAZENECA, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmaceuticals and Biotechnology R & D, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceuticals and Biotechnology R & D.
The Pharmaceuticals and Biotechnology R & D market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pharmaceuticals and Biotechnology R & D market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceuticals and Biotechnology R & D companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
ROCHE
JOHNSON & JOHNSON
MERCK
NOVARTIS
PFIZER
SANOFI
BAYER
BRISTOL-MYERS SQUIBB
ASTRAZENECA
GLAXOSMITHKLINE
ABBVIE
ELI LILLY
BOEHRINGER SOHN
AMGEN
GILEAD SCIENCES
TAKEDA PHARMACEUTICAL
NOVO NORDISK
BIOGEN
ABBOTT
ASTELLAS PHARMA
TEVA PHARMACEUTICAL INDUSTRIES
Segment by Type
Drug
Medical Equipment
Vaccine
Others
Segment by Application
Hospital
Clinic
麻豆原创care
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceuticals and Biotechnology R & D companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pharmaceuticals and Biotechnology R & D 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Drug
1.2.3 Medical Equipment
1.2.4 Vaccine
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Pharmaceuticals and Biotechnology R & D 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 麻豆原创care
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceuticals and Biotechnology R & D 麻豆原创 Perspective (2018-2029)
2.2 Pharmaceuticals and Biotechnology R & D Growth Trends by Region
2.2.1 Global Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharmaceuticals and Biotechnology R & D Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Pharmaceuticals and Biotechnology R & D Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Pharmaceuticals and Biotechnology R & D 麻豆原创 Dynamics
2.3.1 Pharmaceuticals and Biotechnology R & D Industry Trends
2.3.2 Pharmaceuticals and Biotechnology R & D 麻豆原创 Drivers
2.3.3 Pharmaceuticals and Biotechnology R & D 麻豆原创 Challenges
2.3.4 Pharmaceuticals and Biotechnology R & D 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceuticals and Biotechnology R & D Players by Revenue
3.1.1 Global Top Pharmaceuticals and Biotechnology R & D Players by Revenue (2018-2023)
3.1.2 Global Pharmaceuticals and Biotechnology R & D Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Pharmaceuticals and Biotechnology R & D 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceuticals and Biotechnology R & D Revenue
3.4 Global Pharmaceuticals and Biotechnology R & D 麻豆原创 Concentration Ratio
3.4.1 Global Pharmaceuticals and Biotechnology R & D 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceuticals and Biotechnology R & D Revenue in 2022
3.5 Pharmaceuticals and Biotechnology R & D Key Players Head office and Area Served
3.6 Key Players Pharmaceuticals and Biotechnology R & D Product Solution and Service
3.7 Date of Enter into Pharmaceuticals and Biotechnology R & D 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceuticals and Biotechnology R & D Breakdown Data by Type
4.1 Global Pharmaceuticals and Biotechnology R & D Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Pharmaceuticals and Biotechnology R & D Forecasted 麻豆原创 Size by Type (2024-2029)
5 Pharmaceuticals and Biotechnology R & D Breakdown Data by Application
5.1 Global Pharmaceuticals and Biotechnology R & D Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Pharmaceuticals and Biotechnology R & D Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Pharmaceuticals and Biotechnology R & D 麻豆原创 Size (2018-2029)
6.2 North America Pharmaceuticals and Biotechnology R & D 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2018-2023)
6.4 North America Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceuticals and Biotechnology R & D 麻豆原创 Size (2018-2029)
7.2 Europe Pharmaceuticals and Biotechnology R & D 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2018-2023)
7.4 Europe Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceuticals and Biotechnology R & D 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Pharmaceuticals and Biotechnology R & D 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceuticals and Biotechnology R & D 麻豆原创 Size (2018-2029)
9.2 Latin America Pharmaceuticals and Biotechnology R & D 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceuticals and Biotechnology R & D 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Pharmaceuticals and Biotechnology R & D 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Pharmaceuticals and Biotechnology R & D 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ROCHE
11.1.1 ROCHE Company Detail
11.1.2 ROCHE Business Overview
11.1.3 ROCHE Pharmaceuticals and Biotechnology R & D Introduction
11.1.4 ROCHE Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.1.5 ROCHE Recent Development
11.2 JOHNSON & JOHNSON
11.2.1 JOHNSON & JOHNSON Company Detail
11.2.2 JOHNSON & JOHNSON Business Overview
11.2.3 JOHNSON & JOHNSON Pharmaceuticals and Biotechnology R & D Introduction
11.2.4 JOHNSON & JOHNSON Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.2.5 JOHNSON & JOHNSON Recent Development
11.3 MERCK
11.3.1 MERCK Company Detail
11.3.2 MERCK Business Overview
11.3.3 MERCK Pharmaceuticals and Biotechnology R & D Introduction
11.3.4 MERCK Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.3.5 MERCK Recent Development
11.4 NOVARTIS
11.4.1 NOVARTIS Company Detail
11.4.2 NOVARTIS Business Overview
11.4.3 NOVARTIS Pharmaceuticals and Biotechnology R & D Introduction
11.4.4 NOVARTIS Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.4.5 NOVARTIS Recent Development
11.5 PFIZER
11.5.1 PFIZER Company Detail
11.5.2 PFIZER Business Overview
11.5.3 PFIZER Pharmaceuticals and Biotechnology R & D Introduction
11.5.4 PFIZER Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.5.5 PFIZER Recent Development
11.6 SANOFI
11.6.1 SANOFI Company Detail
11.6.2 SANOFI Business Overview
11.6.3 SANOFI Pharmaceuticals and Biotechnology R & D Introduction
11.6.4 SANOFI Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.6.5 SANOFI Recent Development
11.7 BAYER
11.7.1 BAYER Company Detail
11.7.2 BAYER Business Overview
11.7.3 BAYER Pharmaceuticals and Biotechnology R & D Introduction
11.7.4 BAYER Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.7.5 BAYER Recent Development
11.8 BRISTOL-MYERS SQUIBB
11.8.1 BRISTOL-MYERS SQUIBB Company Detail
11.8.2 BRISTOL-MYERS SQUIBB Business Overview
11.8.3 BRISTOL-MYERS SQUIBB Pharmaceuticals and Biotechnology R & D Introduction
11.8.4 BRISTOL-MYERS SQUIBB Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.8.5 BRISTOL-MYERS SQUIBB Recent Development
11.9 ASTRAZENECA
11.9.1 ASTRAZENECA Company Detail
11.9.2 ASTRAZENECA Business Overview
11.9.3 ASTRAZENECA Pharmaceuticals and Biotechnology R & D Introduction
11.9.4 ASTRAZENECA Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.9.5 ASTRAZENECA Recent Development
11.10 GLAXOSMITHKLINE
11.10.1 GLAXOSMITHKLINE Company Detail
11.10.2 GLAXOSMITHKLINE Business Overview
11.10.3 GLAXOSMITHKLINE Pharmaceuticals and Biotechnology R & D Introduction
11.10.4 GLAXOSMITHKLINE Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.10.5 GLAXOSMITHKLINE Recent Development
11.11 ABBVIE
11.11.1 ABBVIE Company Detail
11.11.2 ABBVIE Business Overview
11.11.3 ABBVIE Pharmaceuticals and Biotechnology R & D Introduction
11.11.4 ABBVIE Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.11.5 ABBVIE Recent Development
11.12 ELI LILLY
11.12.1 ELI LILLY Company Detail
11.12.2 ELI LILLY Business Overview
11.12.3 ELI LILLY Pharmaceuticals and Biotechnology R & D Introduction
11.12.4 ELI LILLY Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.12.5 ELI LILLY Recent Development
11.13 BOEHRINGER SOHN
11.13.1 BOEHRINGER SOHN Company Detail
11.13.2 BOEHRINGER SOHN Business Overview
11.13.3 BOEHRINGER SOHN Pharmaceuticals and Biotechnology R & D Introduction
11.13.4 BOEHRINGER SOHN Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.13.5 BOEHRINGER SOHN Recent Development
11.14 AMGEN
11.14.1 AMGEN Company Detail
11.14.2 AMGEN Business Overview
11.14.3 AMGEN Pharmaceuticals and Biotechnology R & D Introduction
11.14.4 AMGEN Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.14.5 AMGEN Recent Development
11.15 GILEAD SCIENCES
11.15.1 GILEAD SCIENCES Company Detail
11.15.2 GILEAD SCIENCES Business Overview
11.15.3 GILEAD SCIENCES Pharmaceuticals and Biotechnology R & D Introduction
11.15.4 GILEAD SCIENCES Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.15.5 GILEAD SCIENCES Recent Development
11.16 TAKEDA PHARMACEUTICAL
11.16.1 TAKEDA PHARMACEUTICAL Company Detail
11.16.2 TAKEDA PHARMACEUTICAL Business Overview
11.16.3 TAKEDA PHARMACEUTICAL Pharmaceuticals and Biotechnology R & D Introduction
11.16.4 TAKEDA PHARMACEUTICAL Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.16.5 TAKEDA PHARMACEUTICAL Recent Development
11.17 NOVO NORDISK
11.17.1 NOVO NORDISK Company Detail
11.17.2 NOVO NORDISK Business Overview
11.17.3 NOVO NORDISK Pharmaceuticals and Biotechnology R & D Introduction
11.17.4 NOVO NORDISK Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.17.5 NOVO NORDISK Recent Development
11.18 BIOGEN
11.18.1 BIOGEN Company Detail
11.18.2 BIOGEN Business Overview
11.18.3 BIOGEN Pharmaceuticals and Biotechnology R & D Introduction
11.18.4 BIOGEN Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.18.5 BIOGEN Recent Development
11.19 ABBOTT
11.19.1 ABBOTT Company Detail
11.19.2 ABBOTT Business Overview
11.19.3 ABBOTT Pharmaceuticals and Biotechnology R & D Introduction
11.19.4 ABBOTT Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.19.5 ABBOTT Recent Development
11.20 ASTELLAS PHARMA
11.20.1 ASTELLAS PHARMA Company Detail
11.20.2 ASTELLAS PHARMA Business Overview
11.20.3 ASTELLAS PHARMA Pharmaceuticals and Biotechnology R & D Introduction
11.20.4 ASTELLAS PHARMA Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.20.5 ASTELLAS PHARMA Recent Development
11.21 TEVA PHARMACEUTICAL INDUSTRIES
11.21.1 TEVA PHARMACEUTICAL INDUSTRIES Company Detail
11.21.2 TEVA PHARMACEUTICAL INDUSTRIES Business Overview
11.21.3 TEVA PHARMACEUTICAL INDUSTRIES Pharmaceuticals and Biotechnology R & D Introduction
11.21.4 TEVA PHARMACEUTICAL INDUSTRIES Revenue in Pharmaceuticals and Biotechnology R & D Business (2018-2023)
11.21.5 TEVA PHARMACEUTICAL INDUSTRIES Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
ROCHE
JOHNSON & JOHNSON
MERCK
NOVARTIS
PFIZER
SANOFI
BAYER
BRISTOL-MYERS SQUIBB
ASTRAZENECA
GLAXOSMITHKLINE
ABBVIE
ELI LILLY
BOEHRINGER SOHN
AMGEN
GILEAD SCIENCES
TAKEDA PHARMACEUTICAL
NOVO NORDISK
BIOGEN
ABBOTT
ASTELLAS PHARMA
TEVA PHARMACEUTICAL INDUSTRIES
听
听
*If Applicable.
